Overview

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.